APRScience.org is an educational project presenting the science of Abortion Pill Rescue therapy as another choice for women facing unplanned pregnancies.
Women Have a Right to Know the Facts About APR Therapy
Physicians have an obligation to inform their patients of safe, ethical, and effective medical treatment options. Yet when it comes to Abortion Pill Rescue (APR) therapy, most physicians and their patients are uninformed. Worse, many are misinformed because they have only seen the widely reported but false claims that APR medical evidence does not exist and that APR is unsafe. APRScience is an educational project dedicated to analyzing and disseminating APR medical evidence. APRScience targets clinicians and researchers who seek access to the latest APR science, providing easy-to-consume charts, figures, and datasets.
Physicians should visit APRN Worldwide to join the medical network. Patients should visit Abortion Pill Reversal for APR therapy.
The American College of Obstetricians and Gynecologists (ACOG) claims that APR is "not supported by science" and suggests that APR therapy "may be associated with an increased risk of hemorrhage." APR medical evidence is preliminary, and more research is needed. However, APR clinical trials, observational studies, and animal investigations have consistently shown that APR is safe and effective. Since 2012, three case series (Delgado 2012; Garratt 2017; Delgado 2018) and two clinical trials (Creinin 2020; Turner 2023) have studied APR therapy in humans. The research shows that two-thirds (66%) of women who change their minds and receive progesterone after starting medication abortion with mifepristone can safely continue their pregnancies.
The chart above presents the results of these studies. The vertical axis shows the continuing pregnancy rate (CPR) reported by each study, broken down by dosing and delivery regime. For instance, Delgado 2018e shows the CPR for oral administration of micronized progesterone (refer to dataset_2 for details). The horizontal red line indicates the ≤25% CPR for mifepristone alone for ≤49 days gestation
(refer to What is the continuing pregnancy rate after mifepristone alone for details). The research shows that the continuing pregnancy rate for mifepristone followed by progesterone is substantially higher than for mifepristone alone.
To learn more about the science that supports APR therapy refer to the questions and answers below.
The most common medication abortion regimen uses two drugs, mifepristone, and misoprostol. Mifepristone is a progesterone antagonist. Misoprostol triggers uterine contractions, expelling the embryo.
Clinicians can stop the effects of mifepristone by increasing progesterone concentration. The progesterone outcompetes mifepristone for the binding sites on the progesterone receptors.
The American Society for Reproductive Medicine reports no increased risk from using progesterone in early pregnancy. Physicians have safely used progesterone in reproductive medicine since the late 1970's.
Complete abortion (embryo demise, uterine evacuation), incomplete abortion (embryo demise, no/incomplete uterine evacuation), or continuing pregnancy (embryo survival).
Evidence from five studies since 2015 shows that the continuing pregnancy rate after ingesting mifepristone alone is generally below ≤25 percent for gestational age ≦49 days.
Evidence shows the continuing pregnancy rate after APR treatment is 65 percent or higher, well above the ≤25 percent continuing pregnancy rate for mifepristone alone.